trial

Obstructive Sleep Apnea Treatment in Serious Mental Illness

NCTId NCT05457127
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Not Yet Recruiting
Enrollment 300 (estimated)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2026-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Not Yet Recruiting
Enrollment
300 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2025-01-01
Primary completion
2026-11
Eligibility
ALL · 40 Years · 70 Years

Interventions & indications

Drugs
Automatic Positive Airway Pressure (APAP)

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor

Sites

1 total
La Jolla, United States

Facts & assertions

4 sourced
Enrollment
300
Phase
NA
Primary Completion Date
2026-11
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
Automatic Positive Airway Pressure (APAP)
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
indication
Obstructive Sleep Apnea of Adult
indication
Bipolar Disorder
indication
Schizoaffective Disorder
indication